Oncogenes and Tumor Suppressor Genes in Small Cell Lung Carcinoma by Pankaj Taneja et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
6 
Oncogenes and Tumor Suppressor Genes in 
Small Cell Lung Carcinoma 
Pankaj Taneja1,2, Robert D. Kendig1,2, Sinan Zhu1,3, Dejan Maglic1,2,3, 
Elizabeth A. Fry1,2 and Kazushi Inoue1,2,3,* 
1The Departments of Pathology,  
2Cancer Biology,  
3Graduate Program in Molecular Medicine,  
Wake Forest University Health Sciences,  
Medical Center Boulevard, Winston-Salem 
USA 
1. Introduction 
Small cell lung cancer (SCLC) makes up almost 15% of all cases of lung cancer and occurs 
almost exclusively in individuals with a history of smoking (Blackhall & Faivre-Finn, 2011; 
Meyerson et al., 2004; Tamasi and Muller, 2011; Walenkamp et al., 2009). However, SCLCs 
differ significantly from NSCLCs in specific genetic alterations that occur. Moreover, 
smoking-damaged bronchial epithelia accompanying SCLCs appears to have undergone 
significantly more acquired genetic damage than is frequently found in NSCLCs. Two 
subtypes of SCLC exist: homogeneous small cell carcinoma and combined SCLC (mixture of 
any non-small cell type) (Meyerson et al., 2004; Tamasi and Muller, 2011). SCLC in its 
advanced stage has an aggressive clinical course and is commonly accompanied by 
paraneoplastic syndromes. Autocrine growth factors, such as neuroendocrine regulatory 
peptides (e.g. bombesin/gastrin-releasing peptide), are prominent in SCLC.  
SCLC is categorized as limited stage disease (LS) when confined to the ipsilateral hemithorax 
and within a single radiation port, while extensive stage disease (ES) includes metastatic 
disease outside the ipsilateral hemithorax (Blackhall & Faivre-Finn, 2011; Meyerson et al., 2004; 
Tamasi and Muller, 2011; Walenkamp et al., 2009). SCLC is sensitive to chemotherapy; 
response rates to front-line agents are often in the range of 60%, with approximately 10% of 
patients achieving a complete response, even in the setting of metastatic disease (Brambilla et 
al., 2009 Jemal et al., 2006). Despite this, the relapse rates are quite high and survival with 
currently available salvage therapy is quite modest. With current therapy, patients with LS-
SCLC have a median survival of 17 months and a 5-year overall survival rate of 12% , while 
patients with ES-SCLC have a median survival of 8.9 months, and a 5-year survival rate of 
approximately 2%. (Brambilla et al., 2009 Jemal et al., 2006; Tamasi and Muller, 2011). This 
article will review the molecular targeted agents, the genetic abnormalities, and therapeutic 
efficacy in SCLC.  
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2. Trp53 gene 
The p53 gene located on chromosome 17p13.1 encodes a nuclear protein that acts as a 
transcription factor and causes cell cycle arrest or apoptosis. Mutations of this gene lead to 
the loss of tumor suppressor function, thereby promoting cellular proliferation. The majority 
of the mutations seen in lung cancers are G to T transversions on the non-transcribed strand, 
suggesting mutagenesis secondary to tobacco smoke. Wild-type p53 protein is present in 
very low levels in normal cells, whereas mutant p53 is present in much greater quantities in 
tumor cells due to its prolonged half-life. In fact, 40–70% of SCLC express abnormal p53 
protein (Wistuba et al., 2001). Inactivating mutations of p53, seen in approximately 90% of 
SCLC, are typically missense mutations in the DNA binding domain and, to a lesser degree, 
homozygous deletions (Demirhan et al., 2010). Preclinical studies have shown that a vaccine 
composed of dendritic cells transduced with a human wild-type P53 containing 
recombinant adenovirus (DC-Ad-p53) causes an antitumor response (Ishihda et al., 1999). 
The differential expression of the mutant P53 gene between normal and tumor cells could 
provide a basis for vaccine therapy.  
Antonia et al. (2006) treated 29 patients with relapsed/refractory ES-SCLC with a vaccine 
consisting of dendritic cells transduced with the full-length wild-type P53 gene delivered 
via an adenoviral vector. Only one patient showed a clinical response to the vaccine therapy. 
Interestingly, there was a high rate of objective clinical responses to chemotherapy (61.9%) 
that immediately followed vaccination. This clinical response to subsequent chemotherapy 
was closely associated with induction of immunologic response to vaccination. Hence, it is 
likely that vaccine therapy could serve as an adjunct to chemotherapy, rather than a primary 
treatment modality. Using this rationale, a current phase I/II trial is evaluating an 
autologous dendritic cell-adenovirus p53 vaccine following standard platinum-etoposide 
chemotherapy in patients with ES- SCLC (Horn et al., 2011). Another approach towards 
vaccination therapy is to target the ganglioside GD3, a cell surface glycosphingolipid 
antigen that is typically expressed on cells of neuroectodermal origin and a subset of T-
lymphocytes (Grant et al., 1999). Studies using SCLC cell lines suggest that these cell lines 
express significant levels of GD3. The anti-idiotypic antibody BEC-2, which mimics the 
structure of the GD3 ganglioside, showed promising results in a pilot study (Grant et al., 
1999). Based on these results, the European Organization for Research and Treatment of 
Cancer (EORTC) performed a randomized phase III study in 515 patients with LS-SCLC 
who were randomized to receive BEC-2 or not as a maintenance treatment following 
standard induction chemotherapy (Giaccone et al., 2005). Although there was no 
improvement in overall survival, progression-free survival, or quality of life in the 
vaccination arm, there was a trend toward prolonged survival in patients who had a 
humoral response. The authors concluded that vaccination strategies may be warranted 
with vaccines that were better able to induce a humoral immune response. 
Yang et al. (2011) evaluated the role of genetic P53 polymorphism in radiation-induced 
pneumonitis (RP), a common dose-limiting toxicity of radiotherapy. In a cohort comprised 
of 253 (188 NSCLC and 65 SCLC) lung cancer patients receiving thoracic irradiation, the P53 
72Arg/Arg genotype was associated with increased radiation-induced pneumonitis risk 
compared with the 72Pro/Pro genotype. Furthermore, the P53 Arg72Pro and ATM-111G>A 
polymorphisms displayed an additive effect in intensifying the risk of developing RP. The 
cross-validation test showed that 63.2% of RP cases could be identified by P53 and ATM 
genotypes. Thus, genotyping P53 and ATM polymorphisms might help proactively identify 
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patients susceptible to developing RP when receiving radiotherapy. A recent report by 
Garcia and co-workers (2010) describe the association of SCLC with ovarian metastases. A 
54-year-old woman with SCLC presented with a left ovarian mass, 4.8 cm in diameter, the 
microscopic appearance of which was identical to the previous bronchoscopic biopsy. 
Molecular analysis of P53 demonstrated an identical point mutation (S215) in both tumor 
sites. Moreover, a P53 DNA polymorphism (P52R) was identified in normal tissue, but 
present in homozygosity in both tumor sites. 
3. Retinoblastoma (RB) gene 
The RB gene, located on chromosome 13q14.11, has been implicated in the regulation of cell 
cycle progression, particularly the G1 to S-phase transition, in part, through inactivation of 
members of the E2F transcription factor family (Modi et al., 2000; Schaffer et al., 2010; 
Wikman et al., 2006). Hypophosphorylated RB is the growth suppressing form that controls 
the transcription factors E2F1, E2F2 and E2F3, which are necessary for the G1/S transition. 
(Modi et al., 2000; Wikman et al., 2006). When bound to hypophosphorylated RB, E2F is in 
its inactive form, causing cell arrest in the G1 phase. The cyclin D1/CDK4 complex 
phosphorylates RB, which in turn releases E2F, allowing its activation and promoting entry 
into S phase. During S phase, cyclin E and CDK2 assert control over the phosphorylation of 
RB (Wikman et al., 2006; Xue et al., 2003). Inactivation of pRB by gross structural alterations 
or point mutations in the RB-1 gene has been described in >90% of all SCLC (Wikman et al., 
2006; Xue et al., 2003). The types of mutations that occur in the RB gene include deletions, 
nonsense mutations and splicing abnormalities. Phosphorylated RB suppresses apoptosis by 
repressing other pro-apoptotic target genes, including apoptotic protease activating factor-1 
(Apaf-1) and caspases.   
There have been numerous reports of RB protein expression in lung cancer (Wikman & 
Kettunen, 2006). Similar to human tumor entities in general, different lung cancer types 
show extensively varying expression patterns:  SCLC and large cell neuroendocrine 
carcinomas (LCNEC) are mostly characterized by loss of RB expression (~90%). Conversely, 
altered expression of RB is rare (~25%) in squamous cell carcinoma (SCC) and 
adenocarcinoma (AC), which comprise most cases of NSCLC (Leversha et al., 2003; Gouyer  
et al., 1998). Rather, NSCLC is attributed to p16INK4a loss or CCND1 overexpression (Schauer 
et al., 1994). Interestingly, a few cases of SCLC display p16INK4a alterations, but retain normal 
RB. Preinvasive bronchial lesions and carcinoid tumors also rarely exhibit abnormal RB 
expression. It is thought that SCLC and other neuroendocrine lung tumors originate from 
the progenitor neural crest that is similar to the origin of RB.  
RB is altered by mutations (20–30%) or small deletions and chromosomal loss (80–90%) in 
SCLC (Mori et al., 1990; Kashii et al., 1994). Even though 58% of neuroendocrine lung 
tumors show low or absent mRNA levels, no hypermethylation has been observed in these 
tumors. In NSCLC, some reports have detected no RB DNA alterations, whereas others, 
somewhat controversially, have found frequent loss of heterozygosity (LOH) (up to 75%) 
and mutations (33%) of RB in SCC (Gouyer et al., 1998; Leversha et al., 2003). DNA 
Alterations of RB have rarely bee described in AC (Sachse et al., 1994). In summary, 
complete loss of RB or a mutant form of RB are present in greater than 90% of SCLC cases 
(Modi et al., 2000). As all normal cells express functional RB, drugs that target cells with 
inactived or deleted RB would be appropriate candidates for testing in patients with SCLC. 
Such drugs include heat shock protein-90 (Hsp90) inhibitors (Rodina et al., 2007). 
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4. BCL2 gene 
BCL2 is an oncogene that plays a major role in suppressing apoptosis and thus in treatment 
resistance (Ilievska et al., 2008; Tudor et al., 2000). Therefore, suppression of BCL2 may 
increase therapeutic efficacy (Ilievska et al., 2008; Lawson et al., 2010; Ziegler et al., 1997). 
Since BCL2 is expressed in the vast majority of SCLC cases, it represents a potential 
therapeutic target in this disease. G3139 (oblimersen) is an 18-base antisense 
phosphorothioate oligonucleotide complementary to the BCL2 mRNA in the region 
encoding the first six amino acids (Reed et al., 1990). Preclinical and clinical studies have 
demonstrated that intravenous administration of G3139 reduces BCL2 protein production 
(Waters et al., 2000). The combination of oblimersen and paclitaxel was evaluated in a phase 
II trial of 12 patients with chemo-refractory SCLC (Rudin et al., 2002). There were no 
objective responses, but four patients had stable disease. The low yield of this small study 
was attributed to the relatively low doses of both agents; the dose of oblimersen chosen may 
have been insufficient to suppress expression of the target gene BCL2, while paclitaxel had 
to be given at a dose clearly below that routinely used. Also, since inhibition of BCL2 
expression may increase therapeutic efficacy of cytotoxic agents, this strategy may be more 
beneficial in patients who responded positively to chemotherapy. In order to test this 
hypothesis, Rudin et al. (2004) combined oblimersen with etoposide and carboplatin in 16 
patients with newly diagnosed extensive stage SCLC. This combination yielded promising 
results with reasonable toxicity and is currently being studied in a randomized phase III 
trial to define an exact role for this molecule. Additionally, a small molecule BCL2 inhibitor, 
AT101, is currently being evaluated in combination with topotecan in patients with 
relapsed/refractory SCLC. ABT-263 has also been identified as a Bcl-2 inhibitor in numerous 
SCLC and leukemia/lymphoma cell lines in vitro and in vivo (Tahir et al., 2010). In another 
study, Knoefel et al. (2011) studied the single-nucleotide polymorphism C-938A to assess the 
potential impact as a genetic marker for response to chemotherapy and outcome prediction 
in 188 Caucasian SCLC patients. Patients carrying the BCL2-938CC genotype showed 
significantly worse time to progression and overall survival than those with the BCL2-
938AA genotype. This genetic marker might particularly impact on treatment strategies 
using BCL2 antisense approaches. 
5. MYC genes 
c-MYC, N-MYC and L-MYC are proto-oncogenes that code for proteins involved in the 
regulation of proliferation, differentiation, and apoptosis (Komiya et al., 2011; Paulson et al., 
2009; Xion et al., 2011). Amplification of the c-MYC oncogene has been observed in various 
human malignancies (Komiya et al., 2011). Studies in small cell lung cancer have suggested 
that although amplification of the MYC family genes is seen in only about 10% of patients 
with newly diagnosed SCLC, this proportion increases following treatment (Komiya et al., 
2011; Paulson et al., 2009; Xion et al., 2011 ; Barr et al., 1998), suggesting that MYC 
expression increases with resistance of SCLC to therapy. Other studies have suggested that 
higher levels of expression of the MYC gene family may play a significant role in the 
carcinogenesis of SCLC (Kumimoto et al., 2002). Protein overexpression is seen with MYC 
activation by gene amplification or transcriptional dysregulation (Komiya et al., 2011). In 
addition, amplification of these genes may have a predictive value, since  tumors with N-
MYC amplification have been associated with poor response to chemotherapy, rapid tumor 
growth, and short survival (Komiya et al., 2011). 
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6. c-KIT receptor 
c-Kit is a tyrosine kinase receptor that, when activated by its ligand stem cell factor (SCF), 
enhances the growth and survival of hematopoietic cells (Reber et al., 2006; Schneider et al., 
2010). Preclinical studies have demonstrated the expression of c-KIT and SCF on almost 70% 
of SCLC cell lines (Reber et al., 2006), suggesting a possible role in the autocrine/paracrine 
stimulation of tumor growth. Almost a third of patients with ES-SCLC  show evidence of c-
kit overexpression by immunohistochemistry (IHC) (Potti et al., 2003; 2005). In a phase II 
study of imatinib in SCLC, Johnson et al. (2003) enrolled 19 patients with extensive disease 
who were either treatment-naïve or had a chemo-sensitive relapse. No activity for imatinib 
was reported, with only one patient showing disease stabilization. A major drawback of this 
study was that 79% of the enrolled patients lacked c-KIT expression. In an attempt to 
improve on these findings, the Cancer and Leukemia Group B (CALGB) refined the study 
design and conducted a similar trial (Dy et al., 2005) in patients with c-KIT overexpression. 
Despite this, the results were similar to those seen in the previous study, with no observed 
responses and only one patient with stable disease for 31 weeks. In a third study, imatinib 
was used as maintenance therapy following cisplatin and irinotecan in patients with ES-
SCLC and c-KIT overexpression in tumor tissue (Schneider et al., 2010). Patients who 
received imatinib did not have any improvement in the progression-free survival, and thus, 
this strategy did not warrant further investigation. One of the reasons for the inactivity of 
imatinib in SCLC may be that the putative cells of origin of SCLC are not developmentally 
dependent on c-KIT (Heinrich et al., 2002), as opposed to hematopoietic stem cells. Another 
reason could be the absence of activating mutations in patients with SCLC in c-KIT exon 11 
that predict for imatinib activity in gastrointestinal stromal tumors (Burger et al., 2003). 
7. Vascular endothelial growth factor (VEGF) and basic fibroblast growth 
factor (bFGF) 
The vascular endothelial growth factor (VEGF) family is comprised of VEGF-A, VEGF-B, 
VEGF-C, VEGF-D and VEGF-E growth factors and their three VEGF receptors (VEGFR 1-3) 
(Tanno et al., 2004; Wójcik et. al., 2010). The VEGF signaling pathway leads to increased 
proliferation, migration, and invasion of endothelial cells, thus mediating tumor 
angiogenesis (Tanno et al., 2004; Sattler & Salgia, 2003). VEGF is a key factor in the 
development of new blood vessels that increases the permeability of microvessels (Thomas 
et al., 2003). High levels of VEGF have been reported in patients with SCLC, which are 
associated with tumor stage, disease progression, resistance to chemotherapy and poorer 
outcomes (Fischer et al., 2007). Studies affecting angiogenesis in SCLC have involved: (1) 
External inhibitors of angiogenesis, chiefly targeting VEGF and its receptor, (2) Endogenous 
inhibitors such as interferons, and, (3) Miscellaneous agents, e.g., thalidomide. SCLCs 
express VEGFR1-3 and VEGFR-2, which are actively involved in tumor growth and invasion 
(Tanno et al., 2004). The VEGF/VEGFR autocrine signaling pathway mediates proliferation 
and metastasis, which can be inhibited with the use of monoclonal antibodies against 
VEGFR-2 and VEGFR-3 in SCLC (Tanno et al., 2004). SU6668, which inhibits VEGFR, c-KIT 
and FGFR, blocks proliferation and angiogenesis in human lung tumor xenografts (Laird et 
al., 2000). In a study of 87 patients with SCLC who underwent primary resection followed 
by adjuvant therapy, microvessel count and expression of VEGF significantly affected 
survival, thereby establishing a role for angiogenesis in SCLC (Lucchi et al., 2002). Another 
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preclinical trial demonstrated that ZD6474, a VEGFR-2 and EGFR kinase inhibitor, 
successfully interfered with VEGF signaling and angiogenesis, leading to decreased 
proliferation and increased apoptosis in SCLC xenographs. Bevacizumab is a recombinant 
humanized monoclonal antibody against VEGF that has been approved by the US Food and 
Drug Administration (FDA) for the treatment of metastatic colon cancer and NSCLC. 
Preliminary reports of bevacizumab following carboplatin and irinotecan treatment in 
patients with LS-SCLC have demonstrated response rates, 1- and 2-year survival rates and a 
safety profile comparable to standard therapy (Raefsky et al., 2005). However, whether the 
addition of bevacizumab increases progression-free and overall survival is currently unclear 
and needs to be studied in a randomized phase III trial. VEGF-tyrosine kinase (VEGF-TK) 
inhibitors have been shown to inhibit downstream signaling pathways that are activated 
following ligand binding to the VEGF receptor. Multiple agents with VEGF-TK inhibitory 
activity are being tested for their utility in therapy of various malignancies. A number of 
small molecules that inhibit VEGFTKs are currently in development, including ZD6474, 
PTK787/ ZKI222584 (vatalanib), AZD2171, BAY 43-9006 (sorafenib), SU11248 (sunitinib), 
and AMG706 (Herbst et al., 2005; Morabito et al., 2009). Trials incorporating SU11248 
(sunitinib), a multi-targeted TK inhibitor, are being planned in SCLC.  
The interferons are a family of naturally-occurring cytokines that have anticancer activity 
through immunomodulatory and antiangiogenic properties (Blackhall & Shepherd, 2004). 
Interferons affect endothelial cells by blocking production of basic fibroblast growth factor 
(bFGF). Patients who achieved a response to chemotherapy were randomized to either 
interferon maintenance or placebo in different randomized trials. In each of those trials, 
administration of interferon was associated with considerable toxicity, although two studies 
showed a trend towards improved survival with interferon treatment (Lebeau et al., 1999). 
Current trials are investigating the role of interferon either as a vaccine or in combination with 
cytotoxic chemotherapy in SCLC. Initial reports of maintenance therapy with thalidomide 
following induction with platinum - etoposide in patients with ES-SCLC have been promising 
(Conney et al., 2005; Ustuner et al., 2008). This approach needs evaluation in the future. 
8. Epidermal growth factor receptor (EGFR) 
Although EGFR expression has been reported to be low in SCLC, gefitinib, an oral EGFR 
tyrosine kinase inhibitor, has been shown to inhibit EGFR signaling in SCLC cell lines 
(Schmid et al., 2010; Tanno et al., 2004). Anecdotal evidence has suggested tumor regression 
in patients with advanced stage SCLC following treatment with gefitinib (Araki et al., 2005; 
Okamoto et al., 2006). This suggests a potential role for gefitinib and other agents targeting 
the EGFR pathway in this disease. Sequist et al. (2011) performed systematic genetic and 
histological analyses of tumor biopsies from 37 patients with drug-resistant NSCLCs 
carrying EGFR mutations. All drug-resistant tumors retained their original activating EGFR 
mutations, and some acquired known mechanisms of resistance including, the EGFR T790M 
mutation or MET gene amplification. Furthermore, some resistant cancers showed 
unexpected genetic changes, such as EGFR amplification and mutations in the PIK3CA gene, 
whereas others underwent a pronounced epithelial-to-mesenchymal transition. 
Surprisingly, five resistant tumors (14%) transformed from NSCLC into SCLC, and were 
sensitive to standard SCLC treatments. Serial biopsies in three patients revealed that genetic 
mechanisms of resistance were lost in the absence of the continued selective pressure of 
EGFR inhibitor treatment, and were sensitive to a second round of treatment with EGFR 
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inhibitors (Sequist et al., 2011). Collectively, these results deepen our understanding of 
resistance to EGFR inhibitors and underscore the importance of repeatedly assessing cancers 
throughout the course of the disease. 
HER2/neu expression in SCLC has been less well studied. Studies have demonstrated 
overexpression of HER2/neu by immunohistochemistry in approximately 13–30% of 
patients with advanced stage SCLC (Micke et al., 2001; Potti et al., 2002, 2003). These studies 
also found that HER2/neu expression was associated with a poor prognosis for patients 
with advanced disease. Based on these findings, the anti-HER2/neu monoclonal antibody 
trastuzumab may be useful as a therapeutic agent in SCLC. 
9. Matrix metalloproteinase (MMP) inhibitors 
Matrix metalloproteinases are involved in extracellular matrix (ECM) degradation (Stetler-
Stevenson et al., 1993), a key process in metastasis. Use of protease inhibitors to limit 
extracellular matrix proteolysis by cancer cells, thereby interfering with tumor cell invasion, 
would thus be an attractive therapeutic target. In a retrospective analysis, elevated MMP 
expression was identified as a negative predictor of survival in SCLC (Michael et al., 1999). 
60 to 70% of tumor cells stained positive by IHC for MMP-1 and -9, while positive signals 
for MMP-11, -13, and -14 were observed in 70 to 100% of tumor cells. Expression of MMP-11 
and MMP-14 was determined to be an independent negative prognostic factor for 
Marimastat, a synthetic, orally administrated, broad spectrum MMPI with activity against 
collagenases, gelatinases, and stromolysins (Brown & Giavazzi 1995). The National Cancer 
Institute of Canada-Clinical Trials Group (NCIC-CTG) and EORTC conducted a randomized 
placebo-controlled trial of marimastat following induction chemotherapy in 532 patients 
with sensitive SCLC (Shepherd et al., 2002). The addition of marimastat after induction 
chemotherapy did not result in improved survival and also had a negative impact on 
quality of life. These disappointing results may be due to patient selection, as MMP 
expression was not studied in these patients. The proteinases MMP11 and MMP14 were 
expressed, a more selective MMPI-targeting these two proteins would arguably be more 
beneficial. In another study, Jumper et al. (2004) evaluated the relationship between 
circulating MMP-9 and tissue inhibitor of matrix metalloproteinase (TIMP-1). Thirty one 
male and female patients with either stage III or IV NSCLC and 17 with either stage III or IV 
SCLC were compared to 117 age-matched non-smoking controls of both sexes. Prior to any 
treatment of the patient, a baseline serum sample was obtained from each of the patients for 
the determination of circulating MMP-9 and TIMP-1. The results indicate that both MMP-9 
and TIMP-1 were elevated in the serum of patients with SCLC or NSCLC when compared to 
the controls. However, the mean values for both MMP-9 and TIMP-1 in the two tumors did 
not differ. The natural physiological relationship between MMP-9 and the inhibitor TIMP-1 
was lost in both SCLC and NSCLC, indicative of abnormal alterations by the tumor. This 
study suggests that advanced lung cancer alters the normal circulatory pattern of MMP-9 
and TIMP-1 a finding that could aid in the understanding of tumor invasion and/or 
metastasis. 
10. Sonic hedgehog pathway 
The hedgehog (HH) signaling pathway is important during embryonic development and 
may be involved in development and progression of several human malignancies (Datta & 
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Datta, 2006; Watkins & Peacock, 2004). In vitro studies have demonstrated extensive 
activation of this pathway in a subset of SCLC cell lines (Watkins et al., 2003). The 
Hedgehog (Hh) pathway is essential in early lung formation and development through 
epithelial-mesenchymal interactions (Peacock & Watkins, 2008; Watkins et al., 2003). The 
signaling cascade is initiated by Hh binding to the Patched-1 receptor (Ptch-1), a twelve 
transmembrane protein. In the absence of Hh ligand, Ptch-1 constitutively inhibits the seven 
transmembrane protein Smoothened (Smo), and renders the pathway inactive. However, 
binding of Hh ligand to Ptch-1 causes the inhibition of Smo to be relieved, which then 
activates a protein complex and downstream transcription of Hh targets in the nucleus, 
including Gli-1 and Ptch-1. Present at low levels in the basal layer of bronchial epithelium in 
the adult, active Hedgehog signaling results in expansion of an intraepithelial cell 
population during airway regeneration induced by naphthalene injury. In SCLC, there is 
ligand-dependent activation of the Hedgehog pathway in a juxtacrine fashion, with adjacent 
cells expressing Sonic hedgehog (Peacock & Watkins, 2008; Watkins et al., 2003). Further, in 
vitro and in vivo studies have demonstrated that SCLC can be inhibited by the steroidal 
alkaloid Hedgehog antagonist, cyclopamine (Watkins et al., 2003; Vestergaard et al., 2006). 
These data support the presence of a progenitor cell in SCLC that remains chemotherapy-
resistant and relies on the Hedgehog developmental pathway, which can be targeted. Gene 
expression analysis on members of this pathway showed that although the key transcription 
factor of this pathway, GL1, was only weakly expressed in cell lines, it was expressed on 
most SCLC tumors studied, thereby suggesting an important role for this pathway for 
tumor growth in vivo (Vestergaard et al., 2006). Thus, the data support the idea that the HH 
pathway may be an ideal therapeutic target in SCLC. Agents that inhibit this pathway, 
cyclopamine and its analog KAAD cyclopamine, will soon be in clinical trials. 
11. mTOR pathway 
Mammalian target of rapamycin (mTOR), a downstream mediator in the PI3K/Akt 
signaling pathway, plays a critical role in the regulation of cell proliferation, survival, 
mobility and angiogenesis (Schmid et al., 2010). Inhibition of this pathway leads to 
inhibition of downstream signaling elements, thereby resulting in cell cycle arrest in the G1 
phase (Chan 2004). Temsirolimus (CCI-779), an inhibitor of mTOR, is being investigated in a 
phase II trial in patients with ES-SCLC in remission following platinum-based 
chemotherapy. Genome-wide gene expression profiling revealed that mutant NRF2 affects 
diverse molecular pathways including the mTOR pathway. Mutant NRF2 upregulates 
RagD, a small G-protein activator of the mTOR pathway, which was also overexpressed in 
primary lung cancer (Shibata et al., 2010). Preliminary results show a prolongation of 
progression-free survival, thereby suggesting significant activity for this agent in SCLC 
(Pandya et al., 2005). Another agent from this class, everolimus (RAD-001), is currently 
being tested in a phase II trial for patients with relapsed SCLC (Schmid et al., 2010). 
12. CD56 (NCAM) 
The neural cell adhesion molecule (NCAM, CD56) is associated with the immunoglobulin 
family and modulates neuroendocrine cell growth, migration, and differentiation (Jensen & 
Berthold, 2007; Kim and Kwon, 2010). CD56 is an isoform encoded by the NCAM gene. 
NCAM is found in almost 100% of SCLC and is also expressed on natural killer cells, 
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neuroendocrine glands, cardiomyocytes, and in the central and peripheral nervous system 
(Kim and Kwon, 2010). Since malignant cells can be influenced by NCAM signaling, it has 
been investigated as a target for anti-cancer therapy (Jensen & Berthold, 2007). N901 is an 
anti-CD56 monoclonal antibody covalently linked to a blocked ricin molecule binds to SCLC 
tumors and cell lines (Lynch, 1993). Initial studies showed promising activity, but were 
hampered by the immune response that developed against the murine monoclonal antibody 
and the ricin molecule, leading to potentially fatal side effects (Fidias et al., 2002). In order to 
overcome this, a humanized version of this antibody covalently bound to the maytasinoid 
(microtubule- depolymerizing compound) effector molecule DM-1 has now been made 
available (BB-10901 or huN901-DM1). Initial studies of this compound have shown evidence 
of efficacy and safety (Fossella et al., 2005) and a phase II trial is currently underway. 
13. Chromosomal alterations 
In SCLC and other epithelial tumors, multiple chromosomal aberrations are found, 
reflecting genomic instability (Balsara& Testa, 2002; Sato et al., 2007.). Loss of the short arm 
of chromosome 3 has been consistently seen in SCLC (Balsara & Testa, 2002). The deletion of 
3p leads to inactivation of three putative tumor-suppressor genes. The majority of SCLCs 
have deletions affecting multiple chromosomal sites, with recurrent losses at 3p, 5q, 13q and 
17p, which are loci with tumor suppressor genes including p53 (Balsara& Testa, 2002). 
Comparative genomic hybridization analyses have revealed that a large number of SCLCs 
harbor gains of 1p, 2p, 3q, 5p, 8q and 19p, regions which encode well-known oncogenes, 
such as MYC and KRAS. SCLC cell lines found to have amplifications of 1p, 2p and 3q, and 
deletion of 18q display a more aggressive phenotype of the disease (Balsara & Testa, 2002). 
Allele loss on chromosome 3p occurs with a frequency greater than 90% in SCLC and is 
believed to be an early event found in lung carcinogenesis (Sato et al., 2007). The loss of the 
fragile histidine triad (FHIT) gene results in the accumulation of diadenosine 
tetraphosphate, stimulating DNA synthesis and proliferation (Sozzi et al., 1996). This gene 
has been localized to 3p14.2 and is believed to be an important tumor suppressor gene 
involved in the pathogenesis of lung cancer (Sozzi et al., 1996; Wistuba et al., 2001). The 
second tumor suppressor gene is believed to be RASSF1A, which is located within a 120 
kilobase region of chromosome 3p21.3 which also contains the FUS1, SEMA3B and SEMA3F 
loci. RASSF1A encodes a protein similar to RAS effector proteins and is inactivated by 
tumor-acquired promoter hypermethylation in 90-100% of SCLC samples (Burbee et al., 
2001; Dammann et al., 2000). ASSF1 is involved in cell cycle pathways, apoptosis and 
microtubule stability (Agathanggelou et al., 2005).  
FUS1 is a novel tumor suppressor gene identified in the human chromosome 3p21.3 region 
where allele losses and genetic alterations occur early and frequently for many human 
cancers. Expression of FUS1 protein is absent or reduced in the majority of lung cancers and 
premalignant lung lesions. Specificially, expression of the FUS1 protein is lost in 100% of 
SCLC cases. Interestingly, restoration of wild-type FUS1 function in 3p21.3-deficient non-
small cell lung carcinoma cells significantly inhibited tumor cell growth by induction of 
apoptosis and alteration of cell cycle kinetics (Ji & Ross, 2008). They report that FUS1 
induces apoptosis through the activation of the intrinsic mitochondrial-dependent and 
Apaf-1-associated pathways and inhibits the function of protein tyrosine kinases including 
EGFR, PDGFR, AKT, c-Abl, and c-Kit. Moreover, intravenous administration of a 
nanoparticle encapsulated FUS1 expression plasmid effectively delivered FUS1 to distant 
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tumor sites and mediated an antitumor effect in orthotopic human lung cancer xenograft 
models (Ji & Ross, 2008). This approach is the rationale for an ongoing FUS1-nanoparticle-
mediated gene delivery clinical trial for the treatment of lung cancer. 
Deletion of a third gene, TGFBR2, located at 3p21.3.22, that encodes the transforming 
growth factor β (TGF-β) type II receptor, has also been described in SCLC (Hougaard et al., 
1999). This nonsense mutation results in the synthesis of a truncated receptor and has been 
linked to exposure to benzo[a]-pyrene, a component of cigarette smoke. The gene coding for 
Retinoic Acid Receptor Beta (RAR-β) is located on chromosome 3p24 (Mattei et al., 1991). 
Retinoic acid plays an important role in lung development and differentiation, acting 
primarily via nuclear receptors. Loss of heterozygosity of RAR-B2 and RAR-B4 isoforms is 
seen in almost all cases of SCLC. Methylation of the promoter region of these two isoforms 
may be responsible for the silencing of their expression in SCLC (Virmani et al., 2000). 
14. Telomerase 
Telomeres are genetic elements present at the ends of linear chromosomes that play an 
important role in stabilizing chromosomes from degradation and cell death (Counter et al., 
1992; Hyer & Silvestri, 2000). Telomerase is a ribonucleoenzyme that compensates for 
telomere shortening during cell division by synthesizing hexameric TTAGGG repeats at the 
end of the chromosomes. The functional unit of this enzyme consists of an RNA component 
hTR, and a catalytic component hTERT. Repression of telomerase in the somatic tissues of 
humans seems to have evolved as a powerful protective barrier against carcinogenesis 
(Newbold, 2002). Studies in patients with neuroendocrine lung tumors have demonstrated 
upregulation of the RNA component of telomerase in 98% of human SCLC (Sarvesvaran et 
al., 1999). Similar studies assessing telomerase activity in small cell lung cancer showed 
increased activity in all specimens analyzed (Hiyama et al., 1995). Zaffaroni et al. (2003) 
studied telomerase activity by the telomeric repeat amplification protocol (TRAP) assay in 
38 neuroendocrine (NE) lung tumors. A positive TRAP signal was observed in 14 of 15 
(93%) SCLCs, 7 of 8 (87%) large-cell NE carcinomas, and only 1 of 15 (7%) typical carcinoid 
tumors. When telomerase activity was correlated with the gene product-based 
immunophenotypic profile of individual tumors, the absence of telomerase activity was 
associated with a lack of BCL-2, P53, c-KIT, and CDK4 expression and presence of RB. Such 
a phenotype was appreciable in most of the carcinoid tumors. Conversely, telomerase-
positive tumors generally showed an immunophenotype consistent with gene product 
alterations (including high expression of BCL-2, P53, and c-KIT, and loss of RB) and were 
characterized by a high proliferative index. These data support the previously reported 
evidence for two genetically unrelated groups of NE lung tumors that have distinct 
phenotypic profiles (Zaffaroni et al., 2003). 
15. Knockout Mouse Models for SCLC 
Contrary to NSCLC, neuroendocrine carcinomas are virtually never found in spontaneous 
or chemically induced murine lung cancer. One reason for this could be that in these murine 
models, a combination of both p53 and Rb mutations is almost never found, unlike most 
human SCLCs. To address this issue, a Cre/lox based deletion of both conditional alleles for 
Rb and p53 was performed by intratracheal instillation with Adeno-Cre (Meuwissen et al., 
2003). After 3 months, foci of neuroendocrine hyperplasia developed through the proximal 
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as well as distal bronchi. After a further 3 months, these early lesions progressed into 
massive lung tumors with histological features typical of SCLC. Interestingly, some early 
type lesions remained even in the presence of extensive SCLC. Consequently, it was of 
importance to determine if the early neuroendocrine lesions are indeed precursors for SCLC 
and, if so, which additional epigenetic events are then needed for progression. 
Immunohistological characterization of the full-blown tumors revealed that they indeed 
shared neuroendocrine features with human SCLC. As in human SCLC all neuroendocrine 
differentiation markers, such as calcitonin gene-related protein (CGRP), neuron-specific 
enolase, synaptophysin, neural cell adhesion molecule, and achaete-scute homolog-1 (ASH-
1) were not expressed. Furthermore, the murine SCLC readily metastasized towards similar 
organs as found with human SCLC (Meuwissen et al., 2003). All primary SCLC, as well as 
their metastases, had all Rb and p53 alleles inactivated. Tumors that retained one WT Rb 
allele were all invariably adenocarcinomas without any neuroendocrine features. Therefore, 
the status of Rb most likely determines if tumors occur with mixed SCLC and NSCLC 
phenotypes, as has been observed in some patients (Brambilla et al., 2000). No lung tumors 
were found in RbF/F mice, which suggested that loss of Rb alone is not enough to initiate lung 
tumorigenesis (Meuwissen et al., 2003) and the additional loss of p53 is needed.  
Not only does Rb loss require additional genetic events to initiate lung tumorigenesis, the 
nature of these complementary lesions also determines which type of lung cancer will 
develop. For instance, RB inactivation and KRas mutations are almost never found together 
in the same human lung cancer. Moreover, the overall mutation rate of RB in human NSCLC 
is very low (Wistuba & Gazdar, 2003). As noted, Adeno-Cre dependent activation of Kras in 
a broad range of lung epithelial cells leads exclusively to the onset of NSCLC. However, 
when LSLKrasG12D transgenes were combined with RbF/F and Rb family p130F/F alleles for 
Adeno-Cre-dependent lung tumor induction, much more advanced adenocarcinomas of 
KrasG12D; Rb-/-; p130-/- genotypes resulted compared to single KrasG12D (Ho et al., 2009). Loss of 
both Rb and p130, albeit to a lesser extent, contributed to Kras dependent NSCLC. Clearly, in 
this genetic context KrasG12D overrules any effect of Rb loss on neuroendocrine 
differentiation.  
Another intriguing observation came from CC10-rtTA; tetO7-Cre; RbF/F mice administered 
doxycycline during early embryogenesis, causing a complete Rb ablation in all bronchial 
Clara cells. However, only increased hypercellular neuroendocrine lesions were detected in 
these mice, and no effect on Clara cell homeostasis could be observed. Alternatively, when 
all three Rb family proteins (Rb, p107 and p130) were inactivated by a truncated SV40 large 
T-antigen oncoprotein (T121) in CC10-T121 mice, severe bronchial hyperplasia with 
complete dedifferentiation of all Clara cells occurred. These results suggest that Rb might be 
specifically required for determining neuroendocrine cell fate, but only in a strict cellular 
and genetic context. The combined evidence from mouse models indicate it is unlikely that 
NSCLC and SCLC develop from similar target cells. It would be more plausible that 
separate, non-identical target cells can develop into different lung cancers, although each 
still depends on specific major genetic pathways.  
Apart from the somatic RbF/F; p53F/F model for SCLC, two other lung cancer models have 
also been associated with pulmonary neuroendocrine tumors. One model made use of 
bitransgenic CC10-hASH1; CC10-SV40 large T system in which progressive neuroendocrine 
dysplasia and aggressive lung adenocarcinoma developed with both focal neuroendocrine 
differentiation (through expression of pro-neural ASH-1 transcription factor) and CC10 
expression (Linnoila et al., 2000). These adenocarcinomas closely resembled human NSCLC 
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with neuroendocrine differentiation (Linnoila et al., 1994). In the other model, the cyclin 
dependent kinase inhibitor p18Ink4c and Men1, a tumor suppressor gene deleted in human 
multiple endocrine neoplasia, were both inactivated. To determine how p18 and p27 
genetically interact with Men1, Pei et al. (2007) characterized p18-Men1 and p27-Men1 
double mutant mice and showed that p18, but not p27, functionally collaborates with Men1 
in suppressing lung tumorigenesis. Lung tumors developed in both Men1+/- and p18-/-; 
Men1+/- mice at a high penetrance and contained both neuroendocrine and non-
neuroendocrine cells. The remaining wild-type Men1 allele was lost in most lung tumors 
from Men1+/- mice, but was retained in most tumors from p18-/-;Men1+/- mice, showing a 
functional collaboration between p18 and Men1 in lung tumor suppression (Pei et al., 2007). 
Phosphorylation of Rb protein at both Cdk2 and Cdk4/Cdk6 sites were significantly 
increased in normal bronchial epithelia and tumor cells derived from p18-/-;Men1+/- mice 
compared to those from single p18-/- or Men1+/- mice. Lung tumors developed in p18-/-;Men1+/- 
mice were multifocal, more heterogeneous, and highly invasive compared to those in either 
p18-/- or Men1+/- mice. These results revealed a previously unrecognized function of p18 in 
lung tumor suppression through collaboration with Men1 to control lung stem cell 
proliferation. To investigate the cellular origin(s) of this cancer, Sutherland et al. (2011) 
assessed the effect of Trp53 and Rb1 inactivation in distinct cell types in the adult lung using 
adenoviral vectors that target Cre recombinase to Clara, neuroendocrine (NE), and alveolar 
type 2 (SPC-expressing) cells. Using these cell type-restricted Adeno-Cre viruses, loss of 
Trp53 and Rb1 efficiently transformed NE and SPC-expressing cells, leading to SCLC, albeit 
SPC-expressing cells were transformed less efficiently (Sutherland et al., 2011). In contrast, 
Clara cells were largely resistant to transformation. Their results indicate that although NE 
cells serve as the predominant cell of origin of SCLC, a subset of SPC-expressing cells are 
also endowed with this ability. 
Increasingly, it is realized that during tumorigenesis a variety of cells are recruited into the 
tumor to provide a range of functions that are associated with tumor progression (Calbo et 
al., 2011). Karnoub and colleagues (2007) showed that mesenchymal stem cells recruited into 
the stroma of breast cancer promote metastasis through CCL5-mediated paracrine signaling, 
thereby emphasizing the relevance of the interactions between tumor cells and the 
surrounding microenvironment. Using the mouse model for simultaneous Rb and p53 
inactivation, Calbo et al. (2011) established primary cultures from 21 murine NSCLCs. They 
found mouse SCLC primary cultures attached to the dishes in 9 of 21 cases, consistent with 
cell culture derived from human SCLC. They seeded single-cell suspensions from 15 mouse 
SCLC cultures in soft agar-containing medium, and isolated individual colonies and 
expanded separately. Most of the obtained clones grew as suspending aggregates of very 
small cells. These cells expressed neuroendocrine protein markers such as synaptophysin, 
achaete-scute complex homolog 1, and neural cell adhesion molecule. They also obtained 
clones grew as a cellular monolayer composed of larger cells with visible cytoplasm and 
spindle-like membrane extensions, spreading on the substrate (mesenchymal cells). This is 
consistent with human SCLC that are often composed of phenotypically different cells with 
either a neuroendocrine or a mesenchymal marker profile. Importantly, these two types of 
cells had a common origin because they shared specific genomic aberrations as 
demonstrated by SKY analysis. Calbo et al. also showed that the transition from 
neuroendocrine to mesenchymal phenotype could be achieved by the ectopic expression of 
oncogenic RasV12 in the former (Calbo et al., 2011). When engrafted as a mixed population, 
the mesenchymal cells endowed the neuroendocrine cells with metastatic capacity, 
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illustrating the potential relevance of tumor cell heterogeneity in dictating tumor properties 
(Calbo et al., 2011). In short, they showed a specific type of tumor heterogeneity of SCLC, in 
which the interaction between clonally derived but diversified subclones alters the behavior 
of the tumor as a whole (Calbo et al., 2011). One outcome was a substantially increased 
metastatic potential, a feature with important clinical ramifications in human SCLC. Tumor 
cell behavior then not only depended on the interactions with stromal cells, but was also 
influenced by interactions with tumor cell variants that fulfill a distinct role in the tumor 
tissue. This study provides a unique system, whereby the mesenchymal compartment of the 
tumor was generated from a separate subclone of SCLC during the tumorigenic process, 
providing the tumor cell population as a whole with new capabilities such as metastatic 
potential. 
16. Xenograft models for SCLC 
For the past three decades, the mainstay of preclinical cancer therapeutic research has been 
the use of human cancer cells lines cultured in vitro and of xenografts derived from these cell 
lines grown in vivo in immunodeficient mice. However, neither model consistently 
predicted the efficacy in clinical trials, resulting in two major barriers to the successful 
translation of new cancer therapeutics. First, resources are expended on drug development 
based on these models that ultimately fail in clinical trials. Second, many potentially useful 
therapies that might be beneficial in humans are discarded because the animal models fail to 
demonstrate efficacy in conventional cell culture and xenograft models. Emerging evidence 
suggests that the process of establishing conventional cell lines from human cancers results 
in distinct and irreversible loss of important biological properties. These include (a) gain or 
loss of gene amplification, (b) the ability to migrate and metastasize, (c) the maintenance of a 
distinct stem cell population, and (d) the preservation of dependency on embryonic 
signaling pathways. These properties are not restored when these conventional cell lines are 
grown as heterotopic or orthotopic xenografts.  
Because SCLC is usually diagnosed by endobronchial biopsy or fine-needle aspiration 
cytology, substantial quantities of fresh or frozen tissues are typically lacking in most tumor 
banks. For this reason, most SCLC researches rely on conventional cell lines, which are often 
chemoresistant because they were derived from patients who had received cytotoxic 
chemotherapy (Phelps et al., 1996). In addition, all of these cell lines have experimental 
limitations and lack the three-dimensional tumor-stromal interactions, which seem to 
significantly affect the response of these cells to chemotherapy (Hodkinson et al., 2007). To 
establish better models for the study of SCLC, Daniel et al. (2009) generated and 
characterized a series of primary xenograft models derived from chemo-naive patients to 
more accurately model SCLC in mice. In parallel, cell lines grown in conventional tissue 
culture conditions were derived from each xenograft line, passaged for 6 months, and then 
reimplanted to generate secondary xenografts. When compared with normal lung, primary 
tumors, xenografts, and cell lines displayed a gene expression signature specific for SCLC 
(Daniel et al., 2009). Comparison of gene expression within the xenograft model identified a 
group of tumor-specific genes expressed in primary SCLC and xenografts that was lost 
during the transition to SCLC cell lines; these genes were not regained when the tumors 
were re-established as secondary xenografts. Such changes in gene expression may be a 
common feature of many cancer cell culture systems, with functional implications for the 
use of such models for preclinical drug development. 
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Bcl-2 is a central regulator of cell survival that is overexpressed in most SCLC tumors and 
contributes to both malignant transformation and therapeutic resistance. Hann et al. (2008) 
compared primary SCLC xenografts prepared from de novo human tumors with standard 
cell line–based xenografts to evaluate a novel and highly potent small molecule inhibitor of 
Bcl-2, ABT-737. ABT-737 induced dramatic regressions in tumors derived from some SCLC 
cell lines. In contrast, only one of three primary xenograft SCLC tumors showed significant 
growth inhibition with ABT-737. Explanations for this apparent difference may include 
relatively low expression of Bcl-2 in the primary xenografts or inherent differences in the 
model systems. The addition of etoposide to ABT-737 in the primary xenografts resulted in 
significantly decreased tumor growth, underscoring the clinical potential of ABT-737 in 
combination therapy. To identify factors that may contribute to resistance to ABT-737 and 
related inhibitors, they isolated resistant derivatives of an initially sensitive cell line–based 
xenograft. Acquired resistance in this model was associated with decreases in the expression 
of the primary target Bcl-2, of proapoptotic partners of Bcl-2 (Bax and Bim), and of Bcl-2:Bim 
heterodimers. Expression profiling revealed 85 candidate genes demonstrating consistent 
changes in gene expression with acquired resistance. These data have specific implications 
for the clinical development of Bcl-2 inhibitors for SCLC and broader implications for the 
testing of novel anticancer strategies in relevant preclinical models.  
17. Conclusions 
There are many distinct genetic pathways present in SCLC, leading to its unique biology 
and clinical features. A better understanding of these basic molecular and cellular changes 
will allow for the development of novel therapeutic strategies. Multiple molecularly 
targeted agents are actively being studied pre-clinically and clinically, with the hope of 
ultimately improving survival of patients with SCLC. Development of targeted therapy in 
small cell lung cancer has significantly lagged behind that of non-small cell lung cancer. 
Etoposide and cisplatin remain the mainstays of first-line SCLC treatment. Although the 
decreasing prevalence of smoking in industrialized countries will lead to decreased 
incidence of SCLC, the burden of disease is shifting to developing countries. Further 
investment in research for this disease is, therefore, warranted. Many phase 1 and 2 studies 
of drugs with potential activity in SCLC and phase 2 and 3 trials to improve radiotherapy 
are underway. Inclusion of patients with SCLC in such trials should be encouraged, 
especially otherwise healthy patients with relapsing or refractory SCLC, for whom 
treatment options are limited. A new, effective, and active combination for extensive-stage 
SCLC would be quickly moved up as a treatment priority.  
SCLC remains a therapeutic challenge despite high initial responses to chemotherapy and 
radiotherapy. The fact that several promising molecularly targeted agents have not shown 
adequate activity in clinical trials does not mean the end of novel targeted therapies for 
SCLC. Nevertheless, a better understanding of SCLC biology and better preclinical models 
of SCLC are needed to improve available therapies.  
The mouse model presented in the study by Meuwissen et al. clearly showed that somatic 
inactivation of both Rb1 and Trp53 alleles in lung epithelial cells readily leads to formation 
of small cell NE tumors. Their histopathologic characteristics and metastasizing capacity 
were strikingly similar to human SCLCs. Their mouse model will prove a valuable tool for 
(1) comparing genotype-phenotype similarities between human SCLC and MSCLC, (2) the 
identification of precursor lesions, and (3) additional factors involved in tumor progression, 
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and (4) ultimately, testing of targeted, novel tumor intervention strategies and 
chemoprevention.  
The identification of specific cell type(s) from which SCLC originates is critical in the 
development of methods for early diagnosis and treatment. By using cell type-restricted 
Adeno-Cre vectors in directing Trp53 and Rb1 loss to distinct cell populations in the adult 
mouse lung, Sutherland et al. showed that NE cells are the predominant cells of origin of 
SCLC. Their study provides additional tools to address questions related to the cell of origin 
of lung cancer, and highlights the importance of specifically targeting NE cells for the 
treatment of SCLC. Their strategy to manipulate specific adult lung cell populations in a 
controlled manner by cell type-restricted somatic gene transfer vectors could help to answer 
the question of whether distinct lung pathologies have a unique cell of origin, and whether 
this cell of origin is a determining factor in the drug resistance profile of the various tumor 
subtypes. 
The work of Calbo et al. showed a specific type of tumor heterogeneity, in which the 
interaction between clonally derived but diversified subclones alters the behavior of the 
tumor as a whole. One outcome was substantially increased metastasis, a feature with 
important clinical ramifications. Thus, tumor cell behavior not only depends on the 
interactions with stromal cells, but also interactions with tumor cell variants that fulfill a 
distinct role in the tumor tissue. Enhanced metastatic capacity serves as an illustrative 
example of crosstalk between specialized tumor cell clones. Disrupting the paracrine 
signaling involved in this interaction is worth further exploring as a strategy to mitigate 
tumor progression in SCLC. 
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